DELAVIRDINE MESYLATE (BioDeep_00000015166)

   


代谢物信息卡片


DELAVIRDINE MESYLATE

化学式: C23H32N6O6S2 (552.1825)
中文名称: 地拉夫定甲磺酸盐
谱图信息: 最多检出来源 Homo sapiens(not specific) 12.5%

分子结构信息

SMILES: CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C.CS(=O)(=O)O
InChI: 1H3,(H,2,3,4)

描述信息

C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent

同义名列表

2 个代谢物同义名

DELAVIRDINE MESYLATE; Delavirdine mesylate



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Venkateswaran Shekar, Abhi Shah, Mohammad Shadid, Jing-Tao Wu, Jayaprakasam Bolleddula, Swapan Chowdhury. An accelerated background subtraction algorithm for processing high-resolution MS data and its application to metabolite identification. Bioanalysis. 2016 Aug; 8(16):1693-707. doi: 10.4155/bio-2016-0101. [PMID: 27460980]
  • Yung-Chih Kuo, Chiu-Yen Chung. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids and surfaces. B, Biointerfaces. 2011 Dec; 88(2):682-90. doi: 10.1016/j.colsurfb.2011.07.060. [PMID: 21865017]
  • Yung-Chih Kuo, Fu-Lung Su. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. International journal of pharmaceutics. 2007 Aug; 340(1-2):143-52. doi: 10.1016/j.ijpharm.2007.03.012. [PMID: 17418986]
  • Patrick F Smith, Robert Dicenzo, Alan Forrest, Mark Shelton, Gerald Friedland, Michael Para, Richard Pollard, Margaret Fischl, Robin DiFrancesco, Gene D Morse. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clinical pharmacokinetics. 2005; 44(1):99-109. doi: 10.2165/00003088-200544010-00004. [PMID: 15634033]
  • Erik J Uhlmann, Pablo Tebas, Gregory A Storch, William G Powderly, Yolanda S Lie, Jeannette M Whitcomb, Nicholas S Hellmann, Max Q Arens. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2004 Nov; 31(3):198-203. doi: 10.1016/j.jcv.2004.03.012. [PMID: 15465412]
  • Quyet Chien Nguyen, Van Hung Nguyen, Bernard D Santarsiero, Andrew D Mesecar, Manh Cuon Nguyen, D Doel Soejarto, John M Pezzuto, Harry H S Fong, Ghee T Tan. New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. Journal of natural products. 2004 Jun; 67(6):994-8. doi: 10.1021/np030469i. [PMID: 15217281]
  • N Gianotti, E Boeri, M Maillard, G Serra, D Ratti, G Gallotta, D Vacchini, Y Tremolada, A Castagna. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. The new microbiologica. 2004 Apr; 27(2 Suppl 1):111-7. doi: NULL. [PMID: 15646073]
  • Mark J Shelton, Ross G Hewitt, John Adams, Andrew Della-Coletta, Steven Cox, Gene D Morse. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrobial agents and chemotherapy. 2003 May; 47(5):1694-9. doi: 10.1128/aac.47.5.1694-1699.2003. [PMID: 12709342]
  • Afsoon D Roberts, Angelike P Liappis, Chris Chinn, David M Parenti, Richard A Muesing, Suzanne Z Schuck, Judy Hsia, Gary L Simon. Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. AIDS (London, England). 2002 Sep; 16(13):1829-30. doi: 10.1097/00002030-200209060-00018. [PMID: 12218397]
  • Naser L Rezk, Richard R Tidwell, Angela D M Kashuba. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Jul; 774(1):79-88. doi: 10.1016/s1570-0232(02)00210-6. [PMID: 12052725]
  • Jose G Castro, Luis Gutierrez. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. The American journal of medicine. 2002 Apr; 112(6):505. doi: 10.1016/s0002-9343(01)01135-4. [PMID: 11959068]
  • Ching-Ling Cheng, Chen-Hsi Chou, Oliver Yoa-Pu Hu. Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Apr; 769(2):297-303. doi: 10.1016/s1570-0232(02)00015-6. [PMID: 11996495]
  • P Villani, M Feroggio, L Gianelli, A Bartoli, M Montagna, R Maserati, M B Regazzi. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. Therapeutic drug monitoring. 2001 Aug; 23(4):380-8. doi: 10.1097/00007691-200108000-00010. [PMID: 11477320]
  • L Bacheler, S Jeffrey, G Hanna, R D'Aquila, L Wallace, K Logue, B Cordova, K Hertogs, B Larder, R Buckery, D Baker, K Gallagher, H Scarnati, R Tritch, C Rizzo. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. Journal of virology. 2001 Jun; 75(11):4999-5008. doi: 10.1128/jvi.75.11.4999-5008.2001. [PMID: 11333879]
  • M Grodesky, E P Acosta, N Fujita, S Mason, J G Gerber. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. HIV clinical trials. 2001 May; 2(3):193-9. doi: 10.1310/lj7m-82qx-5qjj-1r6r. [PMID: 11590527]
  • D Smith, G Hales, N Roth, M Law, J Ray, J Druett, J Mitchell, G Mills, N Doong, R Franklin. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV clinical trials. 2001 Mar; 2(2):97-107. doi: 10.1310/cfyj-26jf-vvru-7an8. [PMID: 11590517]
  • J Q Tran, J G Gerber, B M Kerr. Delavirdine: clinical pharmacokinetics and drug interactions. Clinical pharmacokinetics. 2001; 40(3):207-26. doi: 10.2165/00003088-200140030-00005. [PMID: 11327199]
  • L J Scott, C M Perry. Delavirdine: a review of its use in HIV infection. Drugs. 2000 Dec; 60(6):1411-44. doi: 10.2165/00003495-200060060-00013. [PMID: 11152019]
  • D R Kuritzkes, R L Bassett, V A Johnson, I C Marschner, J J Eron, J P Sommadossi, E P Acosta, R L Murphy, K Fife, K Wood, D Bell, A Martinez, C B Pettinelli. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. AIDS (London, England). 2000 Jul; 14(11):1553-61. doi: 10.1097/00002030-200007280-00011. [PMID: 10983642]
  • M Gangar, G Arias, J G O'Brien, C A Kemper. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. The Annals of pharmacotherapy. 2000 Jul; 34(7-8):839-42. doi: 10.1345/aph.19258. [PMID: 10928391]
  • B Conway. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2000 Jun; 30 Suppl 2(?):S130-4. doi: 10.1086/313850. [PMID: 10860897]
  • J L Casado, K Hertogs, L Ruiz, F Dronda, A Van Cauwenberge, A Arnó, I Garcia-Arata, S Bloor, A Bonjoch, J Blazquez, B Clotet, B Larder. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS (London, England). 2000 Jan; 14(2):F1-7. doi: 10.1097/00002030-200001280-00001. [PMID: 10708276]
  • M F Para, P Meehan, J Holden-Wiltse, M Fischl, G Morse, R Shafer, L M Demeter, K Wood, T Nevin, N Virani-Ketter, W W Freimuth. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrobial agents and chemotherapy. 1999 Jun; 43(6):1373-8. doi: 10.1128/aac.43.6.1373. [PMID: 10348755]
  • B Clotet. Efavirenz: resistance and cross-resistance. International journal of clinical practice. Supplement. 1999 Jun; 103(?):21-5. doi: NULL. [PMID: 10622039]
  • A I Veldkamp, R P van Heeswijk, R M Hoetelmans, P L Meenhorst, J W Mulder, J M Lange, J H Beijnen. Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications. 1999 Apr; 727(1-2):151-7. doi: 10.1016/s0378-4347(99)00081-x. [PMID: 10360434]
  • K A Koeplinger, T J Raub, G E Padbury, Z Zhao. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium. Journal of pharmaceutical and biomedical analysis. 1999 Mar; 19(3-4):399-411. doi: 10.1016/s0731-7085(98)00143-5. [PMID: 10704105]
  • P C Bellman. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS (London, England). 1998 Jul; 12(11):1333-40. doi: 10.1097/00002030-199811000-00015. [PMID: 9708413]
  • E De Clercq. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral research. 1998 Jun; 38(3):153-79. doi: 10.1016/s0166-3542(98)00025-4. [PMID: 9754886]
  • M T Borin, S R Cox, B D Herman, B J Carel, R D Anderson, W W Freimuth. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrobial agents and chemotherapy. 1997 Sep; 41(9):1892-7. doi: 10.1128/aac.41.9.1892. [PMID: 9303380]
  • M Chang, V K Sood, G J Wilson, D A Kloosterman, P E Sanders, M J Hauer, W Zhang, D G Branstetter. Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice. Drug metabolism and disposition: the biological fate of chemicals. 1997 Jul; 25(7):828-39. doi: NULL. [PMID: 9224777]
  • M Chang, V K Sood, D A Kloosterman, M J Hauer, P E Fagerness, P E Sanders, J J Vrbanac. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys. Drug metabolism and disposition: the biological fate of chemicals. 1997 Jul; 25(7):814-27. doi: NULL. [PMID: 9224776]
  • M T Borin, J H Chambers, B J Carel, W W Freimuth, S Aksentijevich, A A Piergies. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral research. 1997 Jun; 35(1):53-63. doi: 10.1016/s0166-3542(97)00011-9. [PMID: 9224961]
  • C L Cheng, D E Smith, P L Carver, S R Cox, P B Watkins, D S Blake, C A Kauffman, K M Meyer, G L Amidon, P L Stetson. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clinical pharmacology and therapeutics. 1997 May; 61(5):531-43. doi: 10.1016/s0009-9236(97)90133-8. [PMID: 9164415]
  • S M Poppe, D E Slade, K T Chong, R R Hinshaw, P J Pagano, M Markowitz, D D Ho, H Mo, R R Gorman, T J Dueweke, S Thaisrivongs, W G Tarpley. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial agents and chemotherapy. 1997 May; 41(5):1058-63. doi: 10.1128/aac.41.5.1058. [PMID: 9145869]
  • M T Borin, J H Chambers, B J Carel, S Gagnon, W W Freimuth. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clinical pharmacology and therapeutics. 1997 May; 61(5):544-53. doi: 10.1016/s0009-9236(97)90134-x. [PMID: 9164416]
  • M Chang, V K Sood, G J Wilson, D A Kloosterman, P E Sanders, M J Hauer, P E Fagerness. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug metabolism and disposition: the biological fate of chemicals. 1997 Feb; 25(2):228-42. doi: . [PMID: 9029054]
  • G D Morse, M A Fischl, M J Shelton, S R Cox, M Driver, M DeRemer, W W Freimuth. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrobial agents and chemotherapy. 1997 Jan; 41(1):169-74. doi: 10.1128/aac.41.1.169. [PMID: 8980774]
  • A J Chaput, R D'Ambrosio, G D Morse. In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral research. 1996 Oct; 32(2):81-9. doi: 10.1016/0166-3542(95)00984-1. [PMID: 8891167]
  • J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq, A Karlsson. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Molecular pharmacology. 1996 Aug; 50(2):394-401. doi: NULL. [PMID: 8700148]
  • R T Davey, D G Chaitt, G F Reed, W W Freimuth, B R Herpin, J A Metcalf, P S Eastman, J Falloon, J A Kovacs, M A Polis, R E Walker, H Masur, J Boyle, S Coleman, S R Cox, L Wathen, C L Daenzer, H C Lane. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial agents and chemotherapy. 1996 Jul; 40(7):1657-64. doi: 10.1128/aac.40.7.1657. [PMID: 8807058]
  • W W Freimuth. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Advances in experimental medicine and biology. 1996; 394(?):279-89. doi: 10.1007/978-1-4757-9209-6_25. [PMID: 8815692]
  • B A Staton, M G Johnson, J M Friis, W J Adams. Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. Journal of chromatography. B, Biomedical applications. 1995 Jun; 668(1):99-106. doi: 10.1016/0378-4347(95)00045-k. [PMID: 7550987]